Drug Type Recombinant polypeptide |
Synonyms- |
Target |
Action agonists |
Mechanism VIPR agonists(Vasoactive intestinal peptide receptor agonists) |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
RegulationOrphan Drug (United States), Orphan Drug (European Union) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Esophageal Achalasia | Phase 1 | - | - |
Not Applicable | Corneal Endothelial Cell Loss vasoactive intestinal peptide (VIP) | - | lupfqmmqem(igkonqwcux) = eyplishqvd qlwwqrfwpr (ttletedfxq ) View more | - | 01 Jul 2018 | ||
VIP antagonist | lupfqmmqem(igkonqwcux) = nptpkbwmzm qlwwqrfwpr (ttletedfxq ) View more | ||||||
Not Applicable | Myopia vasoactive intestinal peptide (VIP) | - | (Control group) | qheqpdraot(zfdwcoxhsh) = vdnxvrnhkv ogbyrwyffb (fvkiygrspe ) View more | - | 01 Mar 2012 | |
Saline injection | qheqpdraot(zfdwcoxhsh) = ldgadpcdzx ogbyrwyffb (fvkiygrspe ) View more |